November 2024 Digital Pathology Roundup

Happy Holidays Everyone! Here is the Digital Pathology Round-Up covering events in November with Imogen Fitt of Signify Research. There will be no December roundup but rather an assessment of the state of the industry and Predictions for 2025 coming in January. Customer Expansions: Ibex Medical Analytics announced significant expansions with existing customers. Alverno Laboratories, operating in Illinois and Indiana, launched Ibex’s AI-based breast cancer diagnostic platform, building on its earlier adoption of prostate diagnostics. A gastric platform is also in development. Meanwhile, France’s Institut Curie deployed Ibex’s prostate solution, with further expansions planned. These updates highlight the slow but steady adoption of AI in pathology, reinforcing its value despite lengthy validation processes. Partnerships: OptraSCAN secured $30M in Series B funding, led by Molbio Diagnostics, to accelerate R&D, expand global sales, and enhance AI pathology tools. Partnerships between genomics and digital pathology firms are expected to deepen as AI solutions advance. Lunit Oncology also announced a collaboration with AstraZeneca to develop AI-powered digital pathology tools for assessing non-small cell lung cancer (NSCLC) risks. Using Lunit’s SCOPE Genotype Predictor, this partnership focuses on identifying key mutations, marking Lunit’s first direct deal with a global pharmaceutical company. Third-Party Integrations: Owkin launched its MSIntuit CRC v2 test for colorectal cancer screening on Proscia’s Concentriq platform and joined the Proscia Ready alliance. The focus now shifts to the implementation of these integrations, whether as pop-ups or embedded tools, and the timeline for deployment. PathAI also announced the integration of tools from Deep Bio, DoMore Diagnostics, Paige, and Visiopharm into its AISight platform. With many IMS platforms adding third-party AI tools, differentiation strategies for vendors in an increasingly crowded market remain a key question